
|Videos|May 24, 2017
Copanlisib as a Treatment for Patients With Relapsed/Refractory Indolent B-Cell Lymphoma
Author(s)Prof Martin Dreyling
Martin Dreyling, MD, professor of medicine, University of Munich Hospital in Grosshadern, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma.




































